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Abstract
The rapid degradation of ribonucleic acids (RNA) by ubiquitous ribonucleases limits the efficacy of
new therapies based on RNA molecules. Therefore, our aim was to characterize the natural
ribonuclease activities on the skin and in blood plasma i.e. at sites where many drugs in development
are applied. On the skin surfaces of Homo sapiens and Mus musculus we observed dominant
pyrimidine-specific ribonuclease activity. This activity is not prevented by a cap structure at the 5'-
end of messenger RNA (mRNA) and is not primarily of a 5'- or 3'-exonuclease type. Moreover, the
ribonuclease activity on the skin or in blood plasma is not inhibited by chemical modifications
introduced at the 2'OH group of cytidine or uridine residues. It is, however, inhibited by the
ribonuclease inhibitor RNasin® although not by the ribonuclease inhibitor SUPERase· In™. The
application of our findings in the field of medical science may result in an improved efficiency of
RNA-based therapies that are currently in development.
Background
The presence of ribonucleases on human and rodent skin
surfaces was described more than 40 years ago.[1,2] Sub-
sequently their distribution within different skin layers
was studied by different techniques.[3-5] However, the
diversity, specificity and activity of extracellular (i.e.
secreted or originating from dead cells) ribonucleases
present on skin was never investigated.
However, information is available on extracellular ribo-
nucleases expressed in internal human organs.[6] These
enzymes belong to the RNaseA protein superfamily. Based
on structural, catalytic and/or biological characteristics
they can be classified into two major groups[7]: the pan-
creatic type (pt) and the non-pancreatic type (npt) ribo-
nucleases. Human pt ribonucleases are similar to bovine
pancreas RNaseA. They are active on poly(A) and double
stranded RNA (dsRNA) and prefer as substrate poly(C)
over poly(U). In contrast, npt ribonucleases are not active
on poly(A) nor on dsRNA substrates and prefer poly(U)
rather than poly(C) as substrate. At present, eight distinct
human extracellular ribonucleases have been described at
the genetic level. All of them are encoded by genes located
on the long arm of chromosome14. At the protein level,
five different ribonuclease activities have been described
for human blood plasma. These ribonucleases range in
size between 14 and 31 kDa.[8]
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of new blood vessels and thus tumor progression [9].
Indeed, Angiogenin that is the first identified tumor
derived secreted angiogenic factor is an extracellular pro-
tein with a pt ribonucleolytic activity. This nuclease fea-
ture is necessary but not sufficient for angiogenin's
angiogenic activity. However, the mechanisms of action
of angiogenin and related poteins (angiogenins) on ang-
iogenesis and in particular the role of the intrinsic RNAse
activity, is still not clearly deciphered (for review see Stry-
dom et al. [10]). For other extracellular ribonucleases it is
suggested that they play a role in the prevention of infec-
tion by microbes [11,12] or RNA-viruses.[13] They might
also control the hypothesized cell-to-cell communication
mediated by the release and uptake of RNA by neighbor-
ing cells.[14] Finally, they may block unwanted activation
of the immune system by dead cells which release RNA
that, if not degraded, would stimulate antigen presenting
cells (APC) through TLR-3, TLR-7 or TLR-8.[15-18]
The characterization of the extracellular ribonuclease
activity has become again an attractive topic at the post-
genomic era, where the development of safe gene thera-
pies is needed for the transfer of basic research to the
clinic. Plasmid DNA or recombinant viruses that were
proposed as delivery vehicles for gene therapy approaches
are associated to potential side effects and have uncon-
trolled half life.[19,20] As an alternative, mRNA, a nucleic
acid with a controlled half life, is being evaluated in pre-
clinical and clinical trials. Several mRNA-based immuni-
zation methods have been developed (reviewed in [21]):
mRNA injected intradermally [22-26], mRNA entrapped
in liposomes and injected subcutaneously or intrave-
nously [27,28], mRNA loaded on gold particles and deliv-
ered intradermally by Gene-Gun [29] and mRNA
transfected in vitro into APC.[30-33]
The quick degradation of mRNA by ubiquitous ribonucle-
ases is one of the safety features of mRNA-based therapies.
This process guaranties that the injected genetic informa-
tion will be completely degraded and cleared from the
body in a short time. The instability, however, puts an
obvious limit on efficacy. Therefore, all mRNA-based ther-
apies would benefit from the utilization of stabilized
mRNA that have enhanced resistance towards ribonucle-
ases contained in physiologic fluids, cell culture media
and on the surface of the skin.
In order to gain more insights into the fundamental func-
tions of extracellular ribonucleases, we investigated their
diversity, their activity and their specificity. With the goal
to enhance mRNA-based therapies, we also tested differ-
ent strategies to stabilize the mRNA with regard to extra-
cellular ribonuclease activity. We report here the
characterization of the ribonuclease activity contained on
the skin surface and in blood plasma and methods to
inhibit them. Our results are relevant for applications in
the field of mRNA-based therapies.
Methods
Animals
BALB/c mice were purchased from Charles River (Sulzfeld,
Germany). The mice were not kept under special patho-
gen free conditions. All animal experiments were per-
formed according to institutional and national guidelines.
Preparation of ribonucleases
Homo sapiens skin surface ribonucleases were repeatedly
isolated from one healthy individual by wetting an area of
~10 cm2 pre-cleaned skin (sterilized and subsequently
washed with soap and water) with 200–300 µl water for
~3 min. During this time the drop of water was several
times pipetted up and down. For Mus musculus, skin sur-
face ribonucleases were isolated by incubating an ear over
night at 4°C in 200–300 µl water. Contact of water with
the cut zone was avoided.
Protein content of skin surface preparations of both ori-
gins was below the detection limit for protein quantifica-
tion by photometric measurements (Roti®-Nanoquant,
Carl Roth, Karlsruhe, Germany). We observed only little
variations in ribonuclease activity of different prepara-
tions as determined in degradation assays.
Peripheral blood from Homo sapiens and Mus musculus was
collected in EDTA containing tubes to avoid coagulation.
Blood plasma was separated by centrifugation for 6 min at
600 g and collected.
RibonucleaseA from Bos taurus pancreas was purchased
from Roche (Mannheim, Germany) and dissolved in
water to 10 mg/ml.
All preparations were aliquoted immediately and stored at
-80°C.
Ribonucleic acids
mRNA was produced by in vitro transcription with T7 RNA
polymerase (T7-Opti mRNA kits, CureVac, Tübingen, Ger-
many). Modified nucleotides were purchased from
TriLink (San Diego, USA). All transcripts contained a
poly(A) tail (70 bases long) and if not otherwise stated a
5'-cap structure. This cap structure was introduced during
in vitro transcription: a fourfold excess of synthetic N7-
Methyl-Guanosine-5'-Triphosphate-5'-Guanosine com-
pared to GTP was used to guaranty that approximately
80% of the synthesized mRNA molecules started with a
cap (whereas the remaining approximately 20% of the
mRNA molecules started with GTP). Synthetic 18-mer
RNA homopolymers were produced by CureVac using thePage 2 of 9
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Amersham (Freiburg, Germany)
Zymogram
After denaturation at 95°C for 2 min in 1 × Laemmli load-
ing buffer, samples were loaded on a SDS-PAGE where the
12, 5% stacking gel contained ~0, 6 mg/ml poly(C). Sub-
sequently to electrophoresis (~2 h at 150 V), the gel was
washed twice for 10 min with 25% (v/v) 2-propanol, 50
mM TrisHCl (pH7, 4) and 5 mM EDTA. The gel was
scanned to document the position of the pre-stained
molecular weight marker proteins (SeeBlue® Plus2, Invit-
rogen, Karlsruhe, Germany). Then, it was further washed
four times for 10 min with 50 mM TrisHCl (pH7, 4) and
5 mM EDTA (washing buffer). Thereafter, the gel was
incubated at 37°C for 17 h in washing buffer supple-
mented with 150 mM NaCl. Ribonuclease activity was vis-
ualized by staining the gel with washing buffer
supplemented with 0, 2%(w/v) toluidine blue O (Sigma,
Munich, Germany) and destaining with washing buffer.
For documentation the gel was scanned (GS-700, Biorad,
Munich, Germany).
Ribonuclease activity assay
Ribonuclease activity was assayed at 37°C in PBS (pH7, 2)
by co-incubation of 0, 16 µg/ml of mRNA or 166 nM of
18-mer homopolymers and the indicated final dilution of
ribonuclease preparations.
Reaction products were analyzed according to the follow-
ing protocols: For mRNA, 6 µl samples were transferred to
6 µl formaldehyde loading buffer containing ethidium
bromide (0, 01 mg/ml) and heat-denatured for 5 min at
80°C. The extend of mRNA digestion was analyzed by
electrophoresis on formaldehyde agarose (FA) gels (1,
2%(w/v) agarose and 0, 65%(w/v) formalin in 1× FA
buffer).
For RNA 18-mer homopolymers 6 µl samples were trans-
ferred to 6 µl formamide, heated for 5 min at 55°C, sepa-
rated by urea-PAGE (42%(w/v) urea and 20%(w/v)
acrylamide(29:1) in 1× TBE) and visualized by epiillumi-
nation of the gels on top of a thin layer chromatography
plate.[34]
Northern blot
The content of FA gels was blotted over night onto
Hybond-N+ membranes (Amersham, Freiburg, Germany)
by the capillary blot technique with 20× SSC as transfer
buffer. After fixation (UV 1300 J/cm2 plus backing 80°C
for 2 h), membranes were equilibrated with hybridization
buffer (5×SSC, 5×Denhardt's and 0, 5%(w/v) SDS) for 30
min at 50°C before the [γ-32P]-labeled 3'-probe (5'-GCA
AGG AGG GGA GGA GGG-3', MWG-Biotech, Ebersberg,
Germany) was added and incubation was continued over
night. After repeated washing with decreasing salt (SSC)
concentrations, the blot was exposed to a phosphor
imager (PI) plate (Fujifilm, Düsseldorf, Germany). After
documentation by scanning the PI plate (BAS-1500, Fuji-
film) the blot was stripped by boiling in 0, 1% SDS (w/v)
and then hybridized to the [γ-32P]-labeled 5'-probe (5'-
TGA GCG TTT ATT CTG AGC TTC TGC-3', Thermo, Ulm,
Germany). Some experiments were also carried out using
first the 5'-probe and subsequently the 3'-probe. Densito-
grams were calculated with the Tina2.09d software
(Raytest, Straubenhardt, Germany).
Electroporation and FACS
Baby hamster kidney (BHK21) cells were grown to 80%
confluence in cell culture medium (RPMI1640 supple-
mented with 100 U/µg/ml penicillin/streptomycin, 2 mM
L-glutamine and 10%(v/v) FCS). Cells were harvested by
trypsin-EDTA, washed once with cell culture medium and
resuspended in PBS. Electroporation of 1–2 × 106 BHK
cells in 4 mm cuvettes was performed at 250 V and 1050
µF in 200 µl PBS with 10 µg mRNA. After transfection,
cells were immediately transferred to a cell culture vessel
and allowed to grow for 15 h. They were harvested with
trypsin-EDTA, fixed with 1%(w/v) formalin in PBS and
analyzed by a FACSCalibur (BD, Heidelberg, Germany)
flow cytometer and the CellQuest™ Pro software (BD).
Ribonuclease inhibitors
The ribonuclease inhibitors RNasin® and SUPERase· In™
were purchased from Promega (Mannheim, Germany)
and Ambion (Huntingdon, UK). These inhibitors were
added to ribonuclease activity assays before the addition
of ribonucleases.
Results
Diversity of extracellular ribonucleases
Human and mouse (BALB/c) extracellular skin ribonucle-
ases (i.e. secreted or originating from dead cells) were
obtained by applying nuclease-free water onto the skin
surface. The recovered ribonuclease-contaminated solu-
tions were aliquoted and stored at -80°C until use. The
proteins contained in the preparations were separated by
SDS-PAGE according to their size. An in-gel enzyme activ-
ity assay (zymogram) was subsequently performed. The
activity profile of skin surface ribonucleases was com-
pared to the one present in blood plasma. On such zymo-
grams (Fig. 1) we found that the major ribonuclease
activity on mouse skin is mediated by a protein of ~13
kDa in size. The protein responsible for the dominant
ribonuclease activity in mouse blood plasma is slightly
smaller (~12 kDa) than the one found on the skin. No or
barely detectable additional ribonuclease activity was
found for proteins of larger or smaller size. In contrast to
the results obtained using mouse preparations, human
preparations contained a broader spectrum of ribonucle-Page 3 of 9
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human skin surface is very similar in size (~13 kDa) to the
one on the mouse skin surface. Moreover, some sub-dom-
inant ribonuclease activities can be observed for seven
larger and one smaller protein. The dominant ribonucle-
ase activity in human blood plasma is performed by a pro-
tein of ~26 kDa. Thus, in humans, the dominant
ribonuclease activity is mediated by a different enzyme on
the skin than in the blood plasma. Because most current
therapies based on mRNA are delivered through the skin,
we focused the rest of our study on the ribonuclease activ-
ity of skin surfaces.
The ribonuclease activity on the skin surface is 
independent of the 5'-cap
Besides its function in nuclear export and translation ini-
tiation the 5'-cap structure is important for the stability of
intracellular mRNA in eukaryotic cells.[35] Therefore, we
tested the capacity of the 5'-cap to protect the mRNA
against extracellular ribonucleases. To this end, we pro-
duced capped and non-capped mRNA. Capped mRNA
was made by adding a 4 fold excess of N7-Methyl-Guano-
sine-5'-Triphosphate-5'-Guanosine compared to GTP to
the in vitro transcription reaction. Thus, approximately
80% of the transcribed mRNA molecules started with a
cap. Purified transcripts were incubated with increasing
concentrations of skin surface ribonucleases and the
mRNA-degradation was analyzed by gel electrophoresis.
The results shown in Fig. 2 indicate that capped and non-
capped mRNA are degraded with the same kinetics. These
experiments demonstrate that the 5'-cap does not influ-
ence the sensitivity of the mRNA to extracellular ribonu-
cleases neither for mouse nor for human skin surface
preparations. Thus, skin surface ribonucleases do not con-
tain a dominant 5'-exonuclease activity or these enzymes
can recognize equally well capped and non-capped
mRNA.
The ribonuclease activity on the skin surface is not 
dominantly of the exonuclease type
Ribonucleases are either endo- or exonucleases. Exonucle-
ases have a predominant role for intracellular mRNA
decay.[35,36] To determine whether the nuclease activity
contained in extracellular ribonuclease preparations
made from skin surface is of the 5'-exo, 3'-exo or endo-
nuclease type, we performed ribonuclease activity assays
followed by northern blots. Theoretically, if the mRNA is
degraded from one end, no degradation fragments should
hybridize with the probe specific for this end. Only the
full length mRNA would be labeled. Experimentally,
using either 5'- or 3'-specific oligonucleotide probes, we
could detect a smear of degradation fragments (Fig. 3A
and 3C). By quantification of the degradation fragments,
we observed an increasing relative activity (percent values
in Fig. 3B and 3D) of fragments smaller than 0, 5 kb (full
RNA degrading proteins of skin surface preparationsFigure 1
RNA degrading proteins of skin surface preparations. 
Zymogram (negative image). Ribonuclease activity in 10 µl 
preparation of blood plasma (prediluted 12, 5× in water) or 
ear surface (1×) from Mus musculus (M.m.) and of blood 
plasma (500×) or hand surface (1×) from Homo sapiens (H.s.) 
is shown and compared to the activity of 500 pg ribonuclease 
A from Bos taurus pancreas. Molecular weights of the most 
prominent bands were estimated by comparison to a molec-
ular weight marker.
Impact of a Cap structure at the 5'end of the substrate RNA n the skin surface ribonuclease activityFigure 2
Impact of a Cap structure at the 5'end of the sub-
strate mRNA on the skin surface ribonuclease activ-
ity. Ribonuclease activity assay (negative images). Non-
capped (-Cap) or capped (+Cap) mRNA coding for enhanced 
green fluorescent protein (eGFP, ~1 kb) was incubated for 
15 min at 37°C with increasing concentrations (indicated by 
the wedge) of preparations from Homo sapiens hand surface 
or Mus musculus ear surface: final dilution 20× or 4×, respec-
tively. Samples without ribonucleases are indicated by a dash.Page 4 of 9
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(course of the graphs in Fig. 3B and 3D) with increasing
duration of digestion for both probes. Thus, the ribonu-
cleases on the surface of human or mouse skin are not par-
ticularly degrading one end of the RNA. Instead, the
activity is due to equally active 5'-and 3'-exonucleases
and/or endonucleases.
The ribonuclease activity at the skin surface is pyrimidine-
specific
To further characterize the ribonuclease activity in skin
surface preparations we sought to determine its substrate
specificity by using synthetic 18-mer homopolymers. Fol-
lowing incubation with skin surface preparations, the oli-
gonucleotides were separated from their degradation
products by urea-PAGE and visualized by the epiillumina-
tion technique. As shown in Fig. 4, poly(A) and poly(G)
oligonucleotides are very resistant to the degradation by
skin surface ribonucleases. On the contrary, poly(C) is
readily degraded by mouse and human extracellular ribo-
nucleases. Human blood plasma ribonucleases show a
similar pattern of activity as human skin surface ribonu-
cleases as far as degradation of poly(C) is concerned but
are different as far as degradation of poly(U) is concerned:
Skin surface ribonucleases do not degrade poly(U)
although blood plasma ribonucleases do. This difference
in substrate specificity between blood plasma and skin
surface ribonucleases correlates with the zymogram
results shown above (Fig. 1): the dominant skin surface
ribonuclease activity is mediated by a different protein
than the one mediating the dominant blood plasma ribo-
nuclease activity. For mice, the ribonuclease activity in
blood plasma is mainly specific for U while the skin sur-
face ribonuclease activity is mainly specific for C. Here
again this difference correlates with the size difference
between the protein mediating the dominant ribonucle-
ase activity in blood plasma and the one mediating the
main ribonuclease activity on skin surface (Fig. 1). To con-
clude, both for mice and humans, the ribonuclease activ-
ity on the skin surface is specific for C. Instead (in mice)
Skin surface exoribonuclease activityFigure 3
Skin surface exoribonuclease activity. Analysis of degra-
dation fragments by Northern Blot. Capped β-galactosidase 
(lacZ, ~3, 5 kb) encoding mRNA was digested for the indi-
cated time by ribonucleases from Homo sapiens hand surface 
(final dilution 4×) and detected by a probe binding close to 
the 5'-end (in A and B) or after stripping of the blot by a 
probe binding close to the 3'-end (in C and D) of the mRNA. 
The densitograms of bound radioactivity for the highlighted 
lanes (0' and 20') of the gels (A and C) are shown in the 
graphs (B and D). PSL means "photo-stimulated lumines-
cence". Percent values given in B and D are the amount of 
radioactivity bound by fragments smaller than 0, 5 kb (filled 
area in B and D) compared to the activity bound by all frag-
ments (filled and open area in B and D).
Substrate specificity of skin surface ribonucleasesFigure 4
Substrate specificity of skin surface ribonucleases. 
Ribonuclease activity assay. 18-mer homopolymers of A, G, 
C or U were digested with ribonucleases of blood plasma 
(final dilution 400×) or ear surface (4×) from Mus musculus 
and with ribonucleases of blood plasma (400×) or hand sur-
face (4×) from Homo sapiens.Page 5 of 9
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specific for U are contained in blood plasma.
2' modified mRNA have no increased resistance towards 
extracellular ribonucleases
Since extracellular ribonucleases recognize pyrimidines
(Fig. 4), an obvious strategy to improve the stability of the
mRNA would be to produce mRNA that contains 2'-mod-
ified cytidines or uridines. To this end, the chemical mod-
ifications have to fulfill two criteria: (i) incorporation of
modified nucleotides by the RNA polymerase during in
vitro transcription and (ii) translation of the modified
mRNA by ribosomes. In our hands, only 4 out of 10 tested
nucleotides (cytidines or uridines with 2'-amino-2'-
deoxy-, 2'-ara-, 2'-azido-2'-deoxy-, 2'-fluoro-2'-deoxy- or
2'-O-methyl sugar moieties, substitutions at position R2
in Fig. 5A) were successfully incorporated in mRNA mol-
ecules using either T7 or SP6 RNA polymerase: 2'-fluoro-
2'deoxycytidine (data not shown), as well as 2'-fluoro-, 2'-
amino-2' and 2'-azido-2'-deoxyuridine. Still, the quality
of the in vitro transcription was affected: a large amount of
abortive (short) mRNA could be seen on agarose gels,
especially when transcribing long genes like LacZ (3.5 kb,
data not shown). When using two modified nucleotides
in the transcription reaction (2'-fluoro-2'deoxycytidine
plus 2'-fluoro-2'deoxyuridine, for example) no full length
mRNA product was obtained. Only one of the four mod-
ified mRNA was translated, albeit at low level compared
to the natural non-modified mRNA, after transfection in
BHK21 cells (Amino U, Fig. 5B). Moreover, none of these
four different 2'-modified mRNA had an increased resist-
ance towards skin surface ribonucleases (Fig. 5C). Thus,
mRNA containing one nucleotide with a 2' modification
are poorly generated by RNA polymerases, are poor tem-
plates for ribosomes in vivo and do not have increased
resistance towards extracellular ribonucleases.
Alternatively to 2' modified nucleotides, sulfur substitu-
tions at the phosphate group (R1, Fig. 5A) of pyrimidines
might enhance mRNA stability. However, we obtained
similar results as for 2' modified nucleotides (data not
shown): poor transcription and no enhanced stability
towards ribonucleases when using one or a combination
of phosphorothioate nucleotide triphosphates.
RNasin® but not SUPERase· In™ protects mRNA from 
ribonuclease activity of skin surfaces
As an alternative to direct chemical modifications, mRNA
can be protected from degradation by ribonuclease-inhib-
itors. One of the well known ribonuclease-inhibitors is
diethyl pyrocarbonate (DEPC). DEPC is a highly reactive
alkylating agent and therefore, very toxic. Consequently, it
can not be used for the protection of mRNA in the context
of mRNA-based therapies. Another class of widely used
ribonuclease inhibitors consists of proteins. Among this
Translation and stability (against skin surface ribonucleases) of cis-modified mRNAFigure 5
Translation and stability (against skin surface ribonu-
cleases) of cis-modified mRNA. Ribonuclease activity 
assay and translation of mRNA. In vitro transcription of 
capped eGFP mRNA was performed with non-modified NTP 
(norm), or with 2'-fluoro-2'-deoxy UTP (Fluoro U), 2'-amino-
2'-deoxy UTP (Amino U) or 2'-azido-2'-deoxyuridine (Azido 
U). See A) for the position (R2) of the substituted residue. B) 
Transcripts were incubated with ribonucleases from Homo 
sapiens hand surface (final dilution 4×) or Mus musculus ear 
surface (20×) at 37°C for increasing time (indicated by the 
wedge): 15 min or 60 min, respectively. Samples without 
ribonucleases are indicated by a dash and were incubated for 
60 min at 37°C. Negative images. C) Transcripts (10 µg) 
were also used to electroporate BHK21 cells. Expression of 
eGFP was monitored in the FL1 channel by FACS analysis. 
For each transcript (open histograms) the expression is 
shown relative to non-transfected cells (filled histograms). 
Numbers indicate the mean of fluorescence intensity of the 
cells transfected with the different transcripts (for non-trans-
fected cells the mean is 6, 1).Page 6 of 9
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tein was originally purified from human placenta. It binds
with high affinity to ribonucleases of the RNaseA family
forming a 1:1 complex [37]. Recently, a new protein capa-
ble of ribonuclease-inhibition was characterized: SUPER-
ase· In™ (Ambion). SUPERase· In™ is reported to have a
broader range of ribonuclease-inhibiting activity than
RNasin®. We compared the two proteins for their ability to
protect in vitro transcribed mRNA against ribonucleases
contained in skin surface preparations. Therefore, the
ribonuclease-inhibitors were mixed with the in vitro tran-
scribed mRNA substrate before being incubated with the
ribonucleases. Surprisingly, only RNasin® could protect
efficiently from ribonuclease activity (Fig. 6). SUPERase·
In™ was as active as RNasin® for the inhibition of purified
RNaseA from Bos taurus pancreas but inefficient in pre-
venting the degradation of mRNA by ribonucleases of the
skin cell surface of Homo sapiens and Mus musculus. Thus,
although SUPERase· In™ has a large spectrum of ribonu-
clease inhibition, it is not well adapted to block the natu-
ral extracellular ribonuclease activity of the skin. Besides,
this experiment suggests that ribonucleases contained in
the skin surface preparation are not dominantly of the
pancreatic (RNaseA-like) type since in this case they
should be equally inhibited by RNasin® and SUPERase·
In™.
Discussion
Towards the characterization of the concerted extracellu-
lar ribonuclease activity (i.e. secreted or originating from
dead cells), we first evaluated the number of proteins with
different sizes capable of ribonuclease activity on the skin
surface or in blood plasma (Fig. 1). Zymograms indicated
that the skin surface contains one dominant ribonuclease
activity mediated by a ~13 kDa protein. In humans, sev-
eral sub-dominant ribonuclease activities are performed
by 7 larger and one smaller protein. The ribonuclease
activity of blood plasma is dominantly mediated by a pro-
tein of ~12 kDa in mice and ~26 kDa in humans. Further
characterization of the ribonuclease activities on the skin
surface indicated that they are not dominantly of a specific
exonuclease type (5'-exo or 3'-exo, Fig. 3), are not
impaired when the substrate contains a 5'-cap structure
(Fig. 2), are specific for pyrimidines (Fig. 4) and can be
efficiently inhibited by RNasin® but not SUPERase· In™
(Fig. 6).
Moreover, using homopolymers as substrates, we found
in all cases (mouse and human, skin surface and blood
plasma) that the extracellular ribonucleases are specific
for pyrimidines and that C is their preferred substrate
(except for ribonucleases contained in mouse blood
plasma where U is preferred, Fig. 4). This result has a great
impact on the development of RNA-based drugs. Since a
similar specificity was observed for the major ribonucle-
ase extracted from mammalian's epidermis [38,39] we
anticipate that the utilization of C-low RNA may be a
method to increase the efficacy of RNA-therapies deliv-
ered transcutaneously, intradermally or subcutaneously.
We investigated whether the preference of extracellular
ribonucleases for pyrimidines was exploited by viruses: a
low U and C content in their transcriptome would be an
advantage for their mRNA half life (especially when the
genome is a RNA molecule). Comparing the mean (±
standard deviation) C content of human mRNA (26, 5 ±
4, 3%) to the mean C content of RNA viruses (25, 1 ± 7,
3% for retro, 23, 1 ± 5, 4% for plus ssRNA and 19, 6 ± 2,
0% for minus ssRNA viruses) we cannot detect a clear ten-
dency for a lower C content in RNA viruses. Thus, viruses
Trans-protection of mRNA against skin surface ribonuclease activityFigure 6
Trans-protection of mRNA against skin surface ribo-
nuclease activity. Ribonuclease activity assay (negative 
images). Capped lacZ mRNA in the absence (w/o) or pres-
ence of the ribonuclease inhibitors RNasin® (R-in, final con-
centration 1 U/µl) or SUPERase· In™ (S-in, 1 U/µl) was 
incubated with ribonucleases of Homo sapiens hand surface 
(final dilution 4×) or of Mus musculus ear surface (20×) or 
with 2, 5 pg/µl ribonuclease A from Bos taurus pancreas at 
37°C for increasing time (indicated by the wedge): Samples 
were taken immediately after addition of ribonucleases as 
well as 15 min and 60 min after. Samples without ribonucle-
ases are indicated by a dash and were not incubated at 37°C.Page 7 of 9
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lar ribonucleases.
In the context of mRNA-based therapies, a possible
method to protect the nucleic acid against degradation by
extracellular ribonucleases would be to modify pyrimi-
dines, rendering them resistant to ribonucleases. Unfortu-
nately, in our reaction conditions, most available UTP or
CTP with a 2' modification were no substrates for in vitro
polymerization with T7 or SP6 polymerase. 2'-fluoro sub-
stitutions were shown to be compatible with in vitro
polymerization [40] but we failed to produce long mRNA
containing modified U and modified C together. A single
2'-modified nucleotide (U or C) could not stabilize the
mRNA sufficiently to resist extracellular ribonucleases
while it abrogated translation in vivo (in transfected cells,
Fig. 5). Thus, the available 2'-modified pyrimidines do
not allow the generation of functional mRNA resistant to
extracellular ribonucleases. Moreover (data not shown),
neither the use of phosphorothioate modified cytidine
[41] (sulfur for oxygen substitution at the phosphate resi-
due, position R1 in Fig. 5A) nor the addition of poly(C) to
the ribonuclease mixture (as a competitor for ribonucle-
ase activity) did improve mRNA stability.
In contrast, the natural ribonuclease inhibitor RNasin®
was efficient in preventing the degradation of mRNA by
extracellular ribonucleases (Fig. 6). RNasin® was also more
effective than SUPERase· In™ for the inhibition of the
ribonucleases present on the skin surface. This result was
unexpected since SUPERase· In™ has a larger reported
spectrum of ribonuclease inhibition compared to RNa-
sin®. Indeed, SUPERase· In™ may be more efficient than
RNasin to inhibit ribonucleases in other applications. In
the case of RNA protection against skin surface ribonucle-
ases, RNasin® might have some unknown relevant ribonu-
clease-specificity.
Our data suggest that mRNA used for therapies as an
injected drug should be delivered together with RNasin®.
RNasin® being a human self protein, is not expected to
have side effects: It should be catabolized naturally in a
relatively short time, it should be not toxic for cells and,
because it is a conserved self protein that is expressed in
several organs [42], it should not trigger an immune
response.
Although our studies document the activities of extracel-
lular ribonucleases present on the skin, they do not pro-
vide an explanation for the role of such molecules. Some
of the extracellular ribonucleases may originate from the
cytosol of dead keratinocytes that constitute the skin sur-
face. This seems to be unlikely since intracellular ribonu-
cleases are mainly of the exonuclease type [35] and we
could demonstrate that this is not the case for extracellular
ribonucleases (Fig. 3). Besides, the characterization at the
DNA level of genes coding for secreted (defined by the
presence of a leader sequence) ribonucleases demon-
strates that there must be a need in higher organisms for
such activities at their surface. All three hypothesized roles
of these ribonucleases on the skin (protection against for-
eign pathogens like RNA-viruses, prevention of the activa-
tion of the immune system by RNA released from dead
cells or inhibition of cell-to-cell interactions through
release-capture of RNA by neighboring cells) are not
mutually exclusive. A role for RNA in cell-to-cell commu-
nication mediated by secretion and recapture of RNA by
neighboring cells was originally suggested by Benner.[14]
In line with this hypothesis we observed a lower content
of ribonuclease activity in fast dividing tissues like tumors
(data not shown and [43]).
Further studies are required to prove whether extracellular
ribonucleases play indeed a role in the control of cell
growth.
Conclusion
RNases present at the skin surfaces recognize pyrimidines
and are not inhibited by a 5'cap structure. As far as enzy-
matically produced messenger RNA are concerned, the
replacement of natural nucleotides by chemically substi-
tuted ones is limited by the poor utilization of such ana-
logs by RNA polymerases. Moreover, chemical
modifications did not decrease RNase-sensitivity and they
impaired translation. For protecting exogenous mRNA
from RNases and keeping an efficient mRNA translation,
we found that the best method is to mix non-modified,
natural mRNA together with the protein RNAsin®. This is
a simple method that can protect the extracellular thera-
peutic mRNA. Particularly in the context of mRNA-based
vaccination, such a trans-protection of the mRNA thanks
to additional RNAsin® can be foreseen as safe method to
improve the mRNA'as half life, thus its penetration in cells
and thereby the efficacy of the vaccine.
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